Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd (Nasdaq: IVVD) granted stock options as inducement awards to new employees.
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) granted stock options as inducement awards to new employees. On June 1, 2026, 17 newly hired non-executive employees received options to purchase an aggregate of 513,500 shares under the 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4).
The options have a $1.22 per share exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting monthly, subject to continuous service.
Positive
- 513,500 stock options granted to support 17 new hires
- Exercise price set at $1.22, aligned with grant date close
- Four-year vesting schedule supports employee retention
- 10-year option term offers long-dated equity incentive
Negative
- Potential future dilution from 513,500 additional option shares
Details
News Market Reaction – IVVD
In the Jun 3 session, IVVD declined 3.51%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- New hires granted
- 17 employees
- Non-executive employees receiving inducement stock options
- Option shares granted
- 513,500 shares
- Aggregate common stock underlying inducement options
- Exercise price
- $1.22 per share
- Closing price on June 1, 2026 grant date
- Vesting period
- 4 years
- Employee stock option vesting schedule
- Initial vesting
- 25% at 1 year
- Cliff vesting on first anniversary of start date
- Option term
- 10 years
- Contractual life of inducement stock options
- Current share price
- $1.14
- Pre-news trading level vs $1.22 option strike
- 52-week range
- $0.483–$3.0699
- IVVD 52-week low and high before this filing
Historical Context
-
Completed enrollment in upsized Phase 3 DECLARATION trial for VYD2311.
-
Announced participation in multiple June 2026 investor events and webcasts.
-
Reported higher revenue but a $41.4M net loss and increased spending.
-
Shared new tolerability analysis for COVID-19 mAb versus vaccines in EVADE/COMPARE.
-
Announced scheduling of Q1 2026 financial results and corporate update call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
The options have a per share exercise price of
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.